BAFFR CAR-T cell therapy (Bio-gene Technology)

N/A

Report date: 2025/10/02 20:00:08

Base Information

Drug NameBAFFR CAR-T cell therapy (Bio-gene Technology)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsB-cell activating factor receptor modulators

TargetsB-cell activating factor receptor

Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesGuangzhou Bio-Gene Technology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Bio-Gene Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A